R&D and Production
Technology Platforms
Our industry-leading, fully integrated platforms leverage cutting-edge technologies that span the entire product lifecycle — from discovery and development to manufacturing and commercialization.
Fully Human Antibody Discovery Platform
Large-Capacity Antibody Library
Built upon a fully human antibody library containing over 240 billion antibodies, it offers extensive diversity and flexibility to facilitate the screening of optimal candidates.
Enhanced Druggability
The inclusion of a fully synthetic antibody library improves antibody druggability, ensuring excellent stability, manufacturability, and binding specificity.
Single-Domain Antibody Library Applications
Equipped with a fully human single-domain antibody library, it significantly advances the development of next-generation therapies such as bispecific CAR-T cells and bi- and multi-specific antibodies.
R&D Achievements and Translation Efficiency
Approximately 20 internal R&D programs have been initiated to date, with four candidates advancing to clinical stages. This validates an efficient discovery-to-CAR-T engine that shortens development cycles, reduces program risks, and expands the exploratory pipeline.
High-throughput CAR-T Cell Therapy Screening and Optimization Platform
Integrated Cutting-Edge Technologies
Combines state-of-the-art single-cell analysis and next-generation sequencing to accelerate CAR-T discovery and optimization.
Comprehensive Functional Profiling
Enables high-throughput screening to allow for rapid evaluation of a large pool of CAR-T lead candidates based on key phenotypic characteristics and functional metrics.
In Vivo CAR-T Platform
Enhanced Targeting
Genetic engineering of viral vector surface proteins improves selective T cell transduction in vivo, minimizing off-target risks.
Cell-Specific Expression
The use of T cell-specific promoters restricts CAR expression to the intended cell type, improving safety.
Immune Evasion
Proprietary envelope modifications prevent the elimination of the viral vector by macrophages and T cells.
Scalable Production
Suspension-adapted packaging cell lines and advanced chromatographic purification boost the yield and quality of viral vectors for clinical applications.
Advanced Manufacturing and CMC Platform
Expert Leadership
Led by an experienced management team with deep expertise in biologics R&D, manufacturing, and quality control.
Comprehensive Functional Profiling
Enables high-throughput screening to allow for rapid evaluation of a large pool of CAR-T lead candidates based on key phenotypic characteristics and functional metrics.
Seamless Transition
Designed to seamlessly support the transition from early-stage development to commercial-scale production, including the development of a "China solution" for global expansion.
Comprehensive Modules
Encompasses plasmid development and production, lentiviral vector development and production (for both ex vivo and in vivo applications), and the distinctive FAST CAR-T platform, each offering specific advantages in CAR-T development.
Clinical Development and Clinical Translational Research Platform
Strategic Joint Laboratory
We have established a joint laboratory with a leading top-tier Chinese hospital, fostering deep integration of research and clinical practice.
Novel Target Discovery
We are focused on exploring potential new targets and investigating novel mechanisms of action to pave the way for first-in-class drugs.
Efficient Clinical Translation
Our strong clinical network and translational expertise enable us to efficiently bridge the gap between preclinical research and clinical application, accelerating candidates into clinical stages.
Integrated Development Model
This integrated approach significantly shortens development timelines and facilitates the generation of critical clinical data to guide further development.